Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions
Objective: SIAXI (NCT02091739), a pivotal double-blind, randomised, placebo-controlled study with a 48-week extension period (EP), assessed the efficacy and safety of incobotulinumtoxinA 75 U or…Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea
Objective: SIAXI (NCT02091739), a pivotal double-blind, randomised, placebo-controlled study with an extension period (EP), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U…Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity
Objective: To study whether incobotulinumtoxinA (INCO), a new, low-antigenicity botulinum toxin (BT) drug, increases BT antibody (BTAB) titers in patients with antibody-induced therapy failure (ABTF)…Cost-utility analysis of flexible interval incobotulinumtoxinA versus onabotulinumtoxinA in the management of blepharospasm and cervical dystonia in Ontario, Canada.
Objective: To carry out a cost-utility analysis for IncoBTX administered with flexible treatment intervals compared to OnaBTX in the management of BL and CD from…A phase 3, placebo-controlled study with an open-label extension: Sustained incobotulinumtoxinA efficacy in upper-limb post-stroke spasticity over 48 weeks
Objective: To assess the efficacy and safety of incobotulinumtoxinA for upper-limb post-stroke spasticity. Background: Botulinum toxin injections are a recommended therapy for limb spasticity. We…Safety and efficacy of escalating doses of incobotulinumtoxinA (400-800U): Increasing improvements in disability due to multifocal upper- and lower-limb spasticity
Objective: To assess the safety and efficacy of escalating incobotulinumtoxinA doses (400-800U) in patients with spasticity. Background: Botulinum toxin treatment at higher doses than currently…SPAsticity in PractiCE (SPACE) – An international, observational study of botulinum toxin type A in spasticity
Objective: To collect real-world routine clinical practice data on effectiveness, safety, and quality of life (QoL) for botulinum toxin type A (BoNT-A) treatment of focal…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.